Navigation Links
Watson Announces Novel Oral Contraceptive Approval
Date:12/22/2010

MORRISTOWN, N.J., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

Watson's new oral contraceptive is a novel alternative to currently available birth control pills.  This pill's unique dosing combination and proven 24-day, active hormone regimen is intended to provide users with a low level of breakthrough bleeding and short, light, predictable periods.

"The approval of this oral contraceptive further strengthens Watson's robust and expanding branded Women's Health portfolio," said Fred Wilkinson, Executive Vice President, Global Brands. "We believe this product is an important addition to the oral contraceptive category, and that its characteristics will make it a desirable choice for women."

The novel contraceptive product, licensed from a subsidiary of Warner Chilcott plc, will be actively marketed to physicians by Watson's Global Brands division beginning in the second quarter 2011.

Recent partnerships with Gedeon Richter, HRA Pharma, Itero Biopharmaceuticals, the Population Council and Columbia Laboratories have enabled Watson to expand its branded offerings and pipeline in women's health to include therapies for infertility, prevention of pre-term birth, uterine fibroids, emergency contraception and long-term contraception.

The approval of the oral contraceptive is based on data from a 12-month, Phase 3, multicenter, open-label study that evaluated the safety and efficacy of the product for pregnancy prevention.  A
'/>"/>

SOURCE Watson Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson and Richter Announce Exclusive License Agreement for Esmya™
2. Watson Confirms Exalgo™ Patent Challenge
3. Watson Announces Pricing of Secondary Offering By Selling Stockholder
4. Watson Announces Commencement of Secondary Offering by Selling Stockholder
5. Watson To Present At The 2010 Credit Suisse Healthcare Conference
6. Watson Confirms Crestor® Patent Challenge
7. Watsons Generic Version of Lotrel ® Receives FDA Approval
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
9. Watson Reaches Settlement with Endo Over Opana® ER
10. Watson Confirms Azilect® Patent Challenge
11. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today ... of cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary ... Clostridium difficile ( C. difficile ) infections. ...
Breaking Medicine Technology:Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5
... TRACON Pharmaceuticals, a biotechnology company that develops targeted ... Phase 1 clinical results from studies of TRC105 and ... at the American Society of Clinical Oncology annual meeting ... programs target unique pathways with the potential for broad ...
... Ascenta Therapeutics announced today that eleven presentations or publications ... pan-Bcl-2 inhibitor, in several major tumor types will be ... (ASCO) Annual Meeting, May 29-June 2, in Orlando, Florida. ... .(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ...
Cached Medicine Technology:TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3
(Date:8/28/2014)... to prevent Ebola virus disease will begin next week ... (NIAID), part of the National Institutes of Health. , ... a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and ... generate an immune system response in healthy adults. Testing ... Bethesda, Maryland. , The study is the first of ...
(Date:8/28/2014)... patients in the study who were on a class ... them as prescribed in the first six months. Patients ... hospitals around the UK involved in the study. , ... and Genomics at The University of Manchester, who led ... correctly, known as ,non-adherence, reduced their effectiveness and may ...
(Date:8/28/2014)... AmeriPride Services, a leading textile services and supply ... its new Customer Portal, an online resource that makes ... for customers. The industry-leading digital tool allows customers to ... company. , Features of the new customer portal include ... and pay bills online , View delivery ...
(Date:8/28/2014)... 2014 Clarity PSO , an ... as a federal Patient Safety Organization (PSO) for another ... Healthcare Research and Quality (AHRQ). Clarity PSO will continue ... services following the true intentions of the Patient Safety ... are proud and eager to continue our journey as ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Genetic ... available throughout the world, with large reference laboratories ... Since laboratories differ with regard to the genetic ... costs, payers may struggle to find the most ... To help clients sort through these differences, Hayes, ...
Breaking Medicine News(10 mins):Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:Arthritis patients failing to take expensive medication, according to new research 2Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... Parents of children with allergies are prone to increased ... ,According to foodconsumer.org, children of parents who ... according to a new study by researchers at Cincinnati ... for allergies are twice as likely to snore. ...
... study conducted on 2500 patients has suggested that women who ... dementia. A Mayo Clinic, Minnesota team has revealed that young ... the age of 38, face a risk enhanced by 260%. ... Neurology. ,Researchers have zeroed in on the possible reason ...
... friend who was a colleague of the murdered nurse, Cheryl Moss ... killed. //When speaking to the press outside the St George's Hospital ... on the Canvey ward. She said that Cheryl was desperate to ... that one among them was murdered in the common smoking spot. ...
... is a genetic disorder that affects the heart's largest artery, ... bottom of the disease and researchers at Johns Hopkins University// ... the blood-pressure drug that has shown promise in recent studies ... Hopkins University said that the Merck's drug appears to prevent ...
... to the fumes of solvents used in house renovations.Contact ... give rise to allergies in young children, said Norbert ... ,Pregnant women should leave renovation work to ... the work area altogether. ,'It is also ...
... culling of poultry began in Niger one of the world’s ... an outbreak of deadly// avian flu near its southern border ... culling of all poultry in affected areas on February 28, ... has now appealed for international help, as it lacked the ...
Cached Medicine News:Health News:Children Of Snoring Parents Are More Likely To Inherit Themselves 2Health News:Cognitive Impairment or Dementia Risk, Pronounced with Ovary loss 2Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3
... The Isoseeds I-125 are brachytherapy sources which ... of localized tumors, especially in the prostate. ... the conclusion of the therapeutic effect, i.e. ... are intended for single use. They are ...
... Four 64 mirrors for complete ... lens rotation. Directly hand held for ... or small holding ring. Small diameter ... gonioscopy without methylcellulose. Advanced technology, multi-layer ...
... Three mirrors of 64, ... small diameter contact surface for ... can be viewed through the ... Multi-layer polymer coating protects mirrors ...
West lacrimal cannula blunt tip with side port....
Medicine Products: